Overview

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Methylphenidate
Criteria
Inclusion Criteria:

- Male and female outpatients 6 to 12 years of age.

- Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSM-IV, as manifested
in clinical evaluation and confirmed by structured interview.

- Participation in structured morning routine (e.g. school, camp, or other organized
activities).

Exclusion Criteria:

- Mental retardation (IQ <75).

- Subjects with a medical condition, or treatment that will either jeopardize subject
safety or affect the scientific merit of the study.

- Subjects with moderate to severe dermatological atopy.

- Subjects with known structural cardiac abnormalities.

- Organic brain disorders.

- Seizure Disorder.

- Subjects with Tourette's syndrome, or a history of psychosis or bipolar disorder.

- Subjects with current comorbid psychopathology that in the investigator's opinion will
warrant immediate treatment or will interfere with the safe execution of the protocol
(i.e. Anxiety or Major Depressive Disorder rated as moderate on CGI).

- Subjects with a history of intolerable adverse effects or non-response to
methylphenidate.

- Pregnant or nursing females.